Buprenorphine
- Generic Name
- Buprenorphine
- Brand Names
- Belbuca, Brixadi, Buprenex, Buprenorphine, Butrans, Sublocade, Suboxone, Subutex, Zubsolv, Buvidal, Sixmo
- Drug Type
- Small Molecule
- Chemical Formula
- C29H41NO4
- CAS Number
- 52485-79-7
- Unique Ingredient Identifier
- 40D3SCR4GZ
- Background
Buprenorphine is a weak partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist used for the treatment of severe pain. It is also commonly used as an alternative to methadone for the treatment of severe opioid addiction. Buprenorphine is commercially available as the brand name product Suboxone which is formulated in a 4:1 fixed-dose c...
- Indication
Buprenorphine is available in different formulations, such as sublingual tablets, buccal films, transdermal films, and injections, alone or in combination with naloxone.
...
- Associated Conditions
- Opioid Dependence, Severe Pain, Moderate Opioid Dependence, Moderate Pain, Severe Opioid Dependence
- Associated Therapies
- -
Pharmacokinetics and Pharmacodynamics of Buprenorphine in Healthy Volunteers
- Conditions
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2006-07-04
- Lead Sponsor
- Danish University of Pharmaceutical Sciences
- Target Recruit Count
- 24
- Registration Number
- NCT00347815
- Locations
- 🇩🇰
Gentofte University Hospital, Hellerup, Denmark
Buprenorphine in the Treatment of Osteoarthritis (OA) in the Elderly
- First Posted Date
- 2006-05-10
- Last Posted Date
- 2011-06-14
- Lead Sponsor
- Napp Pharmaceuticals Limited
- Target Recruit Count
- 219
- Registration Number
- NCT00324038
- Locations
- 🇬🇧
Napp Pharmaceuticals Ltd, Cambridge, United Kingdom
Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back Pain
- Conditions
- Interventions
- First Posted Date
- 2006-04-11
- Last Posted Date
- 2012-09-03
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 660
- Registration Number
- NCT00313014
- Locations
- 🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸Vince and Associates Clinical Research, Overland Park, Kansas, United States
🇺🇸Rheumatology PC, Kalamazoo, Michigan, United States
Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Osteoarthritis Pain
- Conditions
- Interventions
- First Posted Date
- 2006-04-07
- Last Posted Date
- 2012-09-10
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 418
- Registration Number
- NCT00312221
- Locations
- 🇺🇸
Accelovance, San Diego, California, United States
🇺🇸Southern Colorado Clinic, Pueblo, Colorado, United States
🇺🇸Palm Beach Research Center, West Palm Beach, Florida, United States
Buprenorphine Versus Methadone Maintenance in Hepatitis C Patients Receiving Peg-Intron and Rebetol (Study P04279)(TERMINATED)
- Conditions
- First Posted Date
- 2006-01-19
- Last Posted Date
- 2012-11-22
- Lead Sponsor
- Indivior Inc.
- Target Recruit Count
- 128
- Registration Number
- NCT00279565
RCT Comparing Methadone and Buprenorphine in Pregnant Women
- Conditions
- Interventions
- First Posted Date
- 2005-12-30
- Last Posted Date
- 2015-08-05
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 175
- Registration Number
- NCT00271219
- Locations
- 🇺🇸
University of Vermont, Burlington, Vermont, United States
🇺🇸Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸Wayne State University, Detroit, Michigan, United States
Buprenorphine as a Treatment for Individuals Dependent on Analgesic Opioids
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 10
- Registration Number
- NCT00218101
- Locations
- 🇺🇸
University of Texas Health Science Center, Houston, Texas, United States
Science-Based Treatment for Opioid-Dependent Adolescents
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2008-08-12
- Target Recruit Count
- 80
- Registration Number
- NCT00182572
- Locations
- 🇺🇸
Behavioral Science Research Unit, St. Luke's Hospital, New York, New York, United States
Abuse Potential of Buprenorphine and Naloxone in Non-Dependent Opioid Users
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 7
- Registration Number
- NCT00158236
- Locations
- 🇺🇸
Johns Hopkins University (BPRU) Bayview Campus, Baltimore, Maryland, United States
Effects of Buprenorphine/Naloxone Administered in Different Ways For Treating Opioid Dependence
- Conditions
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 10
- Registration Number
- NCT00134914
- Locations
- 🇺🇸
Johns Hopkins University (BPRU) Bayview Campus, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.